Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
Longeveron, Inc.
About
  2. Companies
  3. Longeveron, Inc.
  4. Software
  5. Acute Respiratory Distress Syndrome ...

Acute Respiratory Distress Syndrome (ARDS) Research Program

SHARE

We are conducting a multicenter, double-blinded, randomized, placebo-controlled trial for ARDS due to COVID-19 or influenza virus infection. ARDS can be rapidly induced by a variety of insults, such as coronavirus and influenza virus infection. Approximately 150,000 people experience ARDS in the U.S. annually, with a mortality rate of about 40%. These numbers are increasing as a result of COVID-19, which could become a seasonal epidemic. Older persons, those with Aging Frailty, and those with the Metabolic Syndrome, are at significantly increased risk for severely poor outcomes from ARDS due to viral infection, including prolonged hospitalization and death.

Most popular related searches
COVID 19
influenza virus
infection leading
influenza infected
influenza infection
cytokine storm
lung cell
metabolic syndrome
respiratory distress
coronavirus influenza

Viral infection leading to ARDS can results in severe inflammation called a “cytokine storm”, most pronounced by severely elevated serum levels of C reactive protein (CRP) and interleukin-6 (IL-6). This in turn leads to disruption of the lung cell layers (the endothelial and epithelial barriers), and consequently, to severe inhibition of pulmonary exchange. ARDS can result in long-term adverse effects on patients, such as lung scarring (fibrosis).   As now widely appreciated due to COVID-19, there is a dearth of treatment options available for ARDS, and first-line defense measures often have sub-optimal palliative effects.